In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

doi:10.1186/s12885-016-2635-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

BMC cancer - 2 Aug 2016

Soverini Simona, De Benedittis Caterina, Castagnetti Fausto, Gugliotta Gabriele, Mancini Manuela, Bavaro Luana, Machova Polakova Katerina, Linhartova Jana, Iurlo Alessandra, Russo Domenico, Pane Fabrizio, Saglio Giuseppe, Rosti Gianantonio, Cavo Michele, Baccarani Michele, Martinelli Giovanni

Abstract excerpt

BACKGROUND: Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of disease relapse and progression and not infrequently BCR-ABL1 kinase domain (KD) mutations are implicated in therapeutic failure. In this setting, earlier detection of emerging BCR-ABL1 KD mutations would offer greater chances of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Protein Kinase Inhibitors

Share to Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 27485109
DOI: 10.1186/s12885-016-2635-0
PMCID: PMC4970247

Genes

ABL1
BCR
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.PMID 27485109Read ↗

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.Semantic proximity Read ↗

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.Semantic proximity Read ↗

Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.Semantic proximity Read ↗

Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.Semantic proximity Read ↗

Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.Semantic proximity Read ↗

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.Semantic proximity Read ↗

Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?Semantic proximity Read ↗

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.Semantic proximity Read ↗

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.Semantic proximity Read ↗

Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.Semantic proximity Read ↗

Resistance mutations in CML and how we approach them.Semantic proximity Read ↗

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.